Asset Details
Do you wish to reserve the book?
Immunotherapy and therapeutic vaccines in prostate cancer： an update on current strategies and clinical implications
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Immunotherapy and therapeutic vaccines in prostate cancer： an update on current strategies and clinical implications
Do you wish to request the book?
Immunotherapy and therapeutic vaccines in prostate cancer： an update on current strategies and clinical implications
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Immunotherapy and therapeutic vaccines in prostate cancer： an update on current strategies and clinical implications
2014
Overview
In recent years, immunotherapy has emerged as a viable and attractive strategy for the treatment of prostate cancer. While there are multiple ways to target the immune system, therapeutic cancer vaccines and immune checkpoint inhibitors have been most successful in late-stage clinical trials. The landmark Food and Drug Administration approval of sipuleuceI-T for asymptomatic or minimally symptomatic metastatic prostate cancer set the stage for ongoing phase III trials with the cancer vaccine PSA-TRICOM and the immune checkpoint inhibitor ipilimumab. A common feature of these immune-based therapies is the appearance of improved overall survival without short-term changes in disease progression. This class effect appears to be due to modulation of tumor growth rate kinetics, in which the activated immune system exerts constant immunologic pressure that slows net tumor growth. Emerging data suggest that the ideal population for clinical trials of cancer vaccines is patients with lower tumor volume and less aggressive disease. Combination strategies that combine immunotherapy with standard therapies have been shown to augment both immune response and clinical benefit.
Publisher
Medknow Publications and Media Pvt. Ltd,Medknow Publications & Media Pvt. Ltd,Medknow Publications & Media Pvt Ltd,Wolters Kluwer Medknow Publications
Subject
androgen deprivation; immunotherapy; prostate cancer; therapeutic cancer vaccines
/ Antibodies, Monoclonal - therapeutic use
/ Antigens
/ Biomarkers, Tumor - immunology
/ Cancer Vaccines - therapeutic use
/ Clinical Trials, Phase III as Topic
/ Humans
/ Male
/ Prostatic Neoplasms - immunology
/ Prostatic Neoplasms - secondary
/ Prostatic Neoplasms - therapy
/ Prostatic Neoplasms, Castration-Resistant - immunology
/ Prostatic Neoplasms, Castration-Resistant - secondary
/ Prostatic Neoplasms, Castration-Resistant - therapy
/ Tissue Extracts - therapeutic use
/ Vaccines
/ 临床意义
/ 临床试验
/ 免疫抑制剂
/ 免疫治疗
/ 前列腺癌
/ 治疗性
/ 疫苗
/ 肿瘤生长
